论文部分内容阅读
目的探讨慢性丙型病毒性肝炎 (丙肝 )患者干扰素治疗后干扰素抗体的表达水平及其对干扰素治疗的影响。方法选择 94例慢性丙肝患者采用α2 b-IFN治疗 ,剂量为 3 0 0 m U/次 ,每周 3次 ,3个月为 1个疗程 ,共 3个疗程 ,动态检测抗 -HCV、HCV-RNA及α2 b-IFN-Ig G表达水平。结果α2 b-IFN治疗后抗 -HCV、HCV-RNA阴转率分别为 3 2 .98% (3 1/ 94)和 3 8.3 0 % (3 6/ 94) ,常规治疗组治疗后抗 -HCV、HCV-RNA阴转率分别为 10 .0 0 % (4 / 40 )和 15 .0 0 % (6/ 40 ) ,两者相比有显著性差异 (P<0 .0 1)。干扰素治疗后抗 -IFN-Ig G阳检率为 5 .3 2 % (5 /94) ,与常规治疗组相比无显著性差异 (P>0 .0 5 )。其中第一、第二、第三疗程结束后 ,抗 -IFN-Ig G阳检率分别为 0 (0 / 94)、2 .13 % (2 / 94)和5 .3 2 % (5 / 94) ,干扰素治疗中抗 -IFN-Ig G产生率无显著性差异 (P>0 .0 5 )。结论α2 b-IFN对抗 -HCV、HCV-RNA阴转具有肯定疗效 ,且优于常规治疗 ,其具有一定的免疫原性 ,在治疗过程中可诱导机体产生少量抗α2 b-IFN-Ig G,其对 IFN-α2 b的抑制作用较弱
Objective To investigate the expression of interferon antibody in patients with chronic hepatitis C (HCV) after interferon treatment and its effect on interferon therapy. Methods Ninety-four patients with chronic hepatitis C were treated with α2b-IFN at a dose of 300 u U once per week for 3 months and 3 courses for one course of treatment for 3 cycles to detect anti-HCV and HCV- RNA and α2 b-IFN-Ig G expression levels. Results The negative conversion rates of anti-HCV and HCV-RNA after treatment with α2b-IFN were 32.298% (31/94) and 38.3% (36/94) respectively. The anti-HCV The HCV-RNA negative rates were 10.0% (4/40) and 15.0% (6/40), respectively, with significant difference (P <0.01). The positive rate of anti-IFN-Ig G after interferon treatment was 5.32% (5/94), which showed no significant difference compared with the conventional treatment group (P> 0.05). The positive rates of anti-IFN-Ig G were 0 (0/94), 2.13% (2/94) and 5.32% (5/94) respectively after the first, second and third courses of treatment ), There was no significant difference in anti-IFN-Ig G production in interferon therapy (P> 0.05). Conclusions α2 b-IFN has positive curative effect on anti-HCV and HCV-RNA negative conversion and is better than conventional treatment. It has certain immunogenicity and can induce the body to produce a small amount of anti-α2 b-IFN-Ig G during the course of treatment. Its inhibitory effect on IFN-α2b is weak